Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.03 USD | -2.83% | -8.85% | -81.69% |
Apr. 12 | North American Morning Briefing : Big Banks Kick -2- | DJ |
Mar. 29 | Oragenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Business Summary
Number of employees: 5
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Medical Products
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -71.37% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -71.37% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Joseph Redmond
CEO | Chief Executive Officer | 64 | Dec. 27 |
Janet Huffman
DFI | Director of Finance/CFO | 52 | 23-03-06 |
Kimberly Murphy
BRD | Director/Board Member | 62 | 20-04-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Charles Pope
CHM | Chairman | 73 | 10-06-03 |
John Gandolfo
BRD | Director/Board Member | 63 | 23-10-03 |
Robert Koski
BRD | Director/Board Member | 65 | 09-06-29 |
Director/Board Member | 73 | 10-05-31 | |
Alan Dunton
BRD | Director/Board Member | 70 | 11-03-31 |
Bruce Cassidy
BRD | Director/Board Member | 74 | 23-10-03 |
Kimberly Murphy
BRD | Director/Board Member | 62 | 20-04-30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 4,050,000 | 0 | 0 | 76.77 % |
Stock B | 1 | 4,480,693 | 3,439,769 ( 76.77 %) | 0 | |
Stock C | 0 | 5,417,000 | 0 | 0 |
Company contact information
Oragenics, Inc.
4902 Eisenhower boulevard Suite 125
33634-6310, Tampa
+813 286 7900
http://www.oragenics.comSector
1st Jan change | Capi. | |
---|---|---|
-81.69% | 4.75M | |
-2.31% | 103B | |
+0.56% | 95.71B | |
+1.69% | 22.02B | |
-17.37% | 20.9B | |
-9.30% | 17.85B | |
-41.01% | 16.21B | |
-14.85% | 15.52B | |
+3.21% | 13.86B | |
+33.54% | 12.04B |
- Stock Market
- Equities
- OGEN Stock
- Company Oragenics, Inc.